한스바이오메드
Financials
Valuation Metrics
한스바이오메드's Market Cap is ₩2444B. At end of 2025 it was ₩3936B. Ranked #708 of 2,410 in KR market (top 29%), #302 of 1,631 on KOSDAQ (top 19%), #75 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 244.44B KRW | KR#708/2,410 Sec#75/231 |
| Revenue | 89.78B KRW | KR#1,478/2,410 Sec#91/231 |
| Net Income | -32.08B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 126.41B KRW | KR#1,613/2,410 Sec#126/231 |
| Net Assets | 33.89B KRW | KR#2,133/2,410 Sec#187/231 |
| Employees | 247 | KR#935/2,410 Sec#80/231 |
| Value | ||
| P/B | 7.21x | KR#2,322/2,410 Sec#203/231 |
| P/S | 2.72x | KR#1,981/2,410 Sec#120/231 |
| FCF Yield | -0.57% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -94.65% | KR#2,327/2,410 Sec#214/231 |
| ROA | -25.37% | KR#2,274/2,410 Sec#190/231 |
| Op. Margin | -28.84% | KR#2,163/2,410 Sec#153/231 |
| Revenue Growth | 10.65% | KR#864/2,410 Sec#82/231 |
| Financial Health | ||
| Debt Ratio | 273.03% | KR#2,223/2,410 Sec#223/231 |
| Total Debt | 76.60B KRW | KR#825/2,410 Sec#52/231 |
| FCF | -1.38B KRW | KR#1,297/2,410 Sec#101/231 |
| Cash | 8.15B KRW | KR#1,800/2,410 Sec#161/231 |
| Current Ratio | 0.69x | KR#2,030/2,410 Sec#194/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -36.16% | KR#1,643/2,410 Sec#133/231 |
| 1M Return | -19.34% | KR#1,855/2,410 Sec#182/231 |
| From 52W High | -70.35% | KR#2,060/2,410 Sec#173/231 |
| 1Y MDD | -69.46% | KR#1,940/2,410 Sec#164/231 |
| Trading | ||
| Volume | 46,489 shares | KR#1,138/2,410 Sec#115/231 |
| Trading Value | 794.5M KRW | KR#702/2,410 Sec#73/231 |
| Foreign Own. | 6.28% | KR#701/2,410 Sec#61/231 |
| Per Share | ||
| EPS | -2,249 KRW | KR—/2,410 Sec—/231 |
| BPS | 2,376 KRW | KR#1,996/2,410 Sec#162/231 |
Company Info
Established in 1999, this company manufactures and sells human implantable skin, bone graft materials, and medical devices, having been listed on KOSDAQ in 2009. It is the first bio-company in Asia to successfully commercialize human skin, bone, and silicone implant products, receiving South Korea's first human tissue bank establishment license from the Ministry of Food and Drug Safety. The company is expanding its global business through overseas subsidiaries in the United States, Thailand, and the United Kingdom, and continuously increases R&D investments in new medical technology fields such as tissue engineering and vascular hemostatic devices. HansBiomed was established in 1999 and is headquartered in Songpa-gu, Seoul Metropolitan City.